Clinical Trial Update: GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating GB1211 in combination with pembrolizumab versus pembrolizumab with placebo in patients with metastatic melanoma and head …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma

Drugs mentioned

• GB1211
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Providence Health & Services | Conditions: Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING